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The family of Toll-like receptors (TLRs) function as pattern-recognition receptors (PRRs) that respond to a myriad of highly
conserved ligands. These substrates include pathogen-associated molecular patterns (PAMPs) for the recognition of invading
pathogens, as well as damage-associated molecular patterns (DAMPs) for the recognition of endogenous tissue injury. While the
functions of TLRs are diverse, they have received much attention for their roles in ischemia/reperfusion (I/R) injury of the liver
and other organs. The TLRs play central roles in sensing tissue damage and activating the innate immune system following I/R.
EngagementofTLRsbyendogenousDAMPsactivatesproinﬂammatorysignalingpathwaysleadingtotheproductionofcytokines,
chemokinesandfurtherreleaseofendogenousdangersignals.ThispaperfocusesonthemostrecentﬁndingsregardingTLRfamily
members in hepatic I/R injury and transplantation.
1.Introduction
The liver is a central integrator of the systemic immune
response following acute traumatic or surgical insults. It
is subject to injury and dysfunction following local insults
suchasischemia-reperfusion(I/R),aswellassystemicinsults
including hemorrhagic shock. LiverI/R isa pathophysiologic
process whereby hypoxic organ damage is accentuated fol-
lowingreturnofbloodﬂowandoxygendelivery.Thisprocess
involves activation of the innate immune system, causing
a proinﬂammatory response at the site of injury. Although
the distal cascade of inﬂammatory responses resulting in
organ damage after I/R injury has been studied extensively,
the process by which initial cellular injury after an ischemic
insult contributes to activation of the inﬂammatory response
is poorly understood. Recently, Toll-like receptors (TLRs)
have been shown to be critical for the full induction of the
inﬂammatory response observed in experimental ischemia
and reperfusion. The TLR receptors involved in alerting the
innate immune system appear to be activated by damage-
associated molecular pattern molecules (DAMPs) that are
released during ischemic stress. In this paper, we will
summarize the most recent ﬁndings regarding the role of
TLRs in liver I/R.
2.Toll-Like Receptors
The family of Toll-like receptors are important components
of the innate immune system responsible for recognizing a
variety of exogenous and endogenous molecules [1]. In 1996
it was demonstrated that the Drosophila Toll protein is an
essential part of the immune response to fungal infection in
adult ﬂies in addition to its established role in development
[2]. The identiﬁcation and characterization of the human
Toll homologues soon followed [3]. A total of 13 TLRs have
been identiﬁed in mammals: humans have 10 and mice 12
[4]. While all TLRs are transmembrane proteins, some reside
at the cell surface, and some reside intracellularly. TLR1,
TLR2, TLR4, and TLR6 are found at the cell surface, and all
have an extracellular component comprised of luecine-rich
repeat (LRR) domains. TLR3, TLR7, TLR8, and TLR9 are2 Gastroenterology Research and Practice
intracellular,primarilylocatedintheendoplasmicreticulum.
All TLRs contain a conserved cytoplasmic Toll/IL-1 Receptor
(TIR) domain that is shared by the receptors of the IL-
1 and IL-18 families [5]. These features allow TLRs to
signal through a group of adaptor molecules which also
contain TIR domains. TLRs form heterodimers (TLR1 with
TLR2 and TLR2 with TLR6, e.g.), or homodimerize (TLR4
and TLR9), and undergo conformational changes after
ligand engagement which leads to association of individual
TIR domains. Adaptor molecules are then recruited; these
include MyD88, MyD88-adaptor-like (MAL, also referred
to as TIR domain-containing adaptor protein (TIRAP)),
TIR domain-containing adaptor-inducing IFN-β (TRIF),
TRIF-related adaptor molecule (TRAM), and sterile α-
and armadillo motif-containing protein (SARM) [6]. Most
TLRs utilize MyD88 to initiate intracellular signaling. The
exceptions are TLR3, which interacts with TRIF exclusively,
and TLR4 which is capable of utilizing both MyD88 and
TRIF. MyD88 recruitment initiates activation of additional
intermediate signaling molecules; these proteins include
IL-1R-associated kinase 4 (IRAK4), which phosphorylates
IRAK1,leadingtotherecruitmentofTNFR-associatedfactor
6 (TRAF6) and TGF-β-activated kinase 1 (TAK1). These
events culminate in activation of mitogen-activated protein
kinases p38, c-Jun N-terminal kinase (JNK), and NF-κB
through phosphorylation of I-κK. In contrast to MyD88-
dependent signaling, the TRIF-dependent pathway recruits
TRAF3, ultimately resulting in transcription of interferon-
regulator 3 (IRF3) and production of IFN-β. While the
MyD88 and TRIF-dependent signaling pathways are distinct,
signiﬁcant overlaps exist. For example, TLR4 signaling
through TRIF can result in NF-κB activation, and signaling
through MyD88 can induce activation of IRFs, particularly
IRF1.
TLRs are expressed on several diﬀerent cell types in the
liver, including both parenchymal cells and nonparenchymal
cells. Hepatocytes express low levels of TLR2, TLR3, TLR4,
and TLR5 and are capable of responding to TLR2 and TLR4
ligands [7]. Similarly, biliary epithelial cells express TLR2,
TLR3, TLR4, and TLR5. Kupﬀer cells, the liver’s resident
macrophages, are critical in the pathogenesis of I/R and
express a number of diﬀerent TLRs. Studies suggest that
TLR4 signaling is critical in Kupﬀer cells because they are the
ﬁrst to be exposed to gut-derived endotoxin. When exposed
t op h y s i o l o g i c a ll e v e l so fL P S ,K u p ﬀer cells secrete anti-
inﬂammatory IL-10, suppressing activation of surrounding
immune cells [8–10]. In addition to TLR4, Kupﬀer cells
also express TLR2, TLR3, and TLR9. Most other hepatic
nonparenchymal cells express various TLRs. Hepatic stellate
cells express TLR4 and TLR9, sinusoidal epithelial cells
express TLR4, and subsets of hepatic dendritic cells express
TLR2, TLR3, TLR4, TLR7, and TLR9. The liver contains
a high concentration of natural killer (NK) cells, and they
express TLR1, TLR2, TLR4, TLR7, and TLR9 [11, 12]. It is
worth noting that an exhaustive analysis of the functional
expression of pattern recognition receptors on liver cell
types has not been reported. However, we can conclude that
activation of TLRs during I/R creates a diverse response in
diﬀerent cell types that respond to diﬀerent TLR ligands.
3. LiverI/R
Ischemia/reperfusion injury is a phenomenon whereby tis-
suesexperiencedamageasaresultoftemporarilyinterrupted
blood ﬂow (ischemia) followed by its restoration (reperfu-
sion). Clinically, liver I/R occurs in settings of elective liver
surgery, trauma, shock, and transplantation. Two categories
of hepatic I/R—warm and cold—are similar yet distinct pro-
cesses that share a number of characteristics, both of which
ultimately result in end-organ damage. Warm I/R commonly
occursduringsurgery,trauma,andlow-ﬂowstateswhilecold
I/R is experienced during organ preservation prior to trans-
plantation. The pathophysiology of liver I/R injury includes
both direct cellular damage as a result of the ischemic insult
aswellasdelayeddysfunctionfollowingreperfusionresulting
from activation of the immune system. The distal interacting
elements in the cascade of inﬂammatory responses resulting
in organ damage following hepatic I/R injury have been
extensively studied. However, proximal events that initiate
damage during I/R are less well characterized. The most
recent work in this ﬁeld points to a critical role for activation
of TLRs after I/R as initiating events in the pathogenesis of
I/R injury.
3.1. Warm Ischemia Reperfusion Injury. The process of
warm I/R injury involves activation of immune pathways
and is dominated by hepatocellular injury. While all cells
types in the liver are involved in the process, Kupﬀer
cells, the resident macrophages of the liver, are a key cell
type involved in the earliest stages of I/R injury. Amongst
their many functions, one of the most important is the
production of reactive oxygen species (ROS). They were
discovered to be an important source of ROS during I/R
in the 1980s [13–15]. Normally, ROS production is useful
in eliminating circulating pathogens and is the mechanism
responsible for the “respiratory burst” observed when these
cells are activated. However, excessive ROS after an ischemic
insult is detrimental. While damage occurs directly from
ischemia-induced oxidant stress on many cell types during
the early phase of injury, ROS from Kupﬀer cells also
contributes to the activation of inﬂammatory pathways that
lead to neutrophil accumulation in the liver, resulting in
additional, prolonged injury. Thus, Kupﬀer cell-derived ROS
are involved in the pathogenesis of I/R injury through direct
oxidant-mediated damage and by augmenting the local
activation of proinﬂammatory pathways.
Another hallmark of I/R injury is the release of cytokines
and chemokines from cells at the site of injury. Kupﬀer
cells, in addition to releasing ROS, are also principally
responsible for the release of cytokines during I/R. Both
Tumor necrosis factor-alpha (TNFα) and Interluekin-1 (IL-
1) are released from Kupﬀer cells within minutes following
reperfusion [16, 17] and promote damage through a number
of mechanisms. Brieﬂy, these cytokines recruit neutrophils
by promoting upregulation of neutrophil integrins and also
activate and recruit CD4+ T cells to the site of injury [18–
20]. Additionally, they promote the local production of
key chemokine molecules which both attract and activate
neutrophils [21–23]. Together, these events culminate inGastroenterology Research and Practice 3
hepatocellulardamageanddeath,resultinginelevatedserum
transaminase levels and organ damage. While the extent
of damage is dependent on a number of factors, including
severity of the ischemic insult, all of the pathological factors
contributing to I/R injury also share the commonality that
they are, in part, dependent on TLR signaling. Thus, while
multiple signaling networks are responsible for coordinating
the inﬂammatory response during I/R injury, TLRs are
critical in initiating and mediating these eﬀects.
3.2. Cold Ischemia Reperfusion Injury. Cold I/R occurs in
the setting of solid organ transplantation after a donor
graft is harvested. Before cold storage, the organ is perfused
with a preservation solution and remains ischemic until
it is transplanted into the recipient. When the graft is
reperfused cold I/R occurs. In contrast to warm I/R, cold I/R
is dominated by damage to the sinusoidal endothelial cells
and disruption of the microcirculation rather than damage
to the hepatocytes. While cold storage times that occur in
human transplantation vary greatly, animal studies focus
on storage times of up to 18 hours, though some extend
cold storage to 24 hours or more. In addition to cold I/R
injury, liver transplantation involves additional factors such
as immunologic tolerance and rejection [24, 25].
4. Role of Endogenous DAMPs in I/R
Acute, ischemic, and sterile tissue injury activates the innate
immune system in a way similar to pathogenic infections
from microbes, viruses, and fungi. This phenomenon occurs
because pattern recognition receptors, including the TLRs,
are capable of recognizing both PAMPs and DAMPs, leading
to activation of similar downstream signaling cascades. Since
the ﬁrst report that an endogenous molecule, Heat Shock
protein 60, could activate TLR4 signaling [26], a number
of additional TLR-activating DAMPs have been discovered
including hyaluronan, ﬁbrinogen, heparin sulfate, High
Mobility Group Box Protein 1 (HMGB1), and DNA [1].
During I/R, DAMPs come into contact with TLR-expressing
cells through several diﬀerent mechanisms. Direct cellular
damage from oxidative stress during ischemia results in the
passive release of DAMPs from necrotic cells; additionally,
they are liberated from the cell matrix by proteases. Lastly,
it appears that DAMP release from stressed cells may be
a regulated mechanism. Recent reports show that DAMP-
mediated TLR activation itself regulates the additional
release of a number of danger signals, and therefore TLR
signaling may function in an autocrine/paracrine fashion
that culminates in excessive innate immune activation and
organ damage.
5.TLR4 inLiverI/R
Amongst the most studied TLR in hepatic I/R is TLR4.
Buetler et al. were the ﬁrst to discover that TLR4 is a sensor
for bacterial lipopolysaccharide (LPS) [27], and subsequent
studies showed that TLR4 also plays a role in a number of
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Figure 1: Role of TLR4 in hepatic I/R injury. Signaling through the
pattern recognition receptor TLR4 mediates multiple inﬂammatory
pathways following hepatic I/R. The activation of TLR4 signaling is
dependent, in part, on circulating DAMPs. Downstream signaling
events include the TRIF-dependent activation of IRF3, the pro-
duction of Type I IFN, and upregulation of CXCL10. Additionally,
TLR4 activation of IRF1 promotes release of the DAMP, HMGB1.
Lastly, TLR4 activation is thought to suppress the cytoprotective
HO-1 pathway.
acute sterile injury models, including liver I/R (Figure 1)
[28].
5.1. Warm I/R. The involvement of TLR4 in warm I/R injury
was ﬁrst described by Wu and colleagues in 2004. This
study used a model of partial hepatic I/R and showed that
mice deﬁcient in TLR4 signaling experienced signiﬁcantly
less liver damage compared to their wild-type counterparts.
TLR4-deﬁcient mice had signiﬁcantly lower levels of serum
aspartate transaminase levels (AST), as well as decreased
levels of TNF-α mRNA and myeloperoxidase (MPO) after
I/R [29]. Other groups have subsequently published similar
ﬁndings, all of which show that TLR4-deﬁcient mice experi-
ence less injury and inﬂammation after warm I/R [30–33].
These studies provided clues that TLR4 activation during
I/R promotes damage through secretion of cytokines and
recruitment of inﬂammatory cells to the liver. In addition
to reduced secretion of proinﬂammatory mediators, Shen
et al. also found that the protective Heme Oxygenase-1
(HO-1) pathway was upregulated in TLR4 deﬁcient mice,
suggesting that suppression of this pathway downstream of
TLR4 activation is another damage-promoting mechanism
during I/R [31]. Another model of sterile, ischemic injury is
hemorrhagic shock (HS). HS results in systemic hypoperfu-
sionandI/R-likedamagetotheliver.Inadditiontodatafrom
I/R models, we have shown that the liver damage induced
by hemorrhagic shock is also strongly TLR4-dependent4 Gastroenterology Research and Practice
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Figure 2: TLRs coordinate the response to hepatic I/R injury. Toll-
like receptors are proximal to most elements of hepatic I/R injury.
Following an ischemic insult, TLR activation by circulating DAMPs
sets oﬀ signaling cascades in multiple cell types that coordinates the
inﬂammatory response. Both TLR4 and TLR9 activation on hepatic
nonparenchymal cells promotes production of proinﬂammatory
cytokines, leading to additional neutrophil recruitment and organ
damage. TLR4 activation has also been shown to augment the
release of circulating DAMPs and may suppress protective cellular
pathways.
[34], suggesting a common mechanism between these two
ischemic insults.
One important question from early studies was the
agent(s) responsible for activating TLR4 after I/R. While
TLR4 is capable of recognizing a number of substrates, our
laboratory has shown a key role for the endogenous nuclear
molecule HMGB1 [32]. Administration of recombinant
HMGB1 prior to I/R resulted in a signiﬁcant increase in
hepatocellular damage in TLR4 WT but not TLR4-deﬁcient
mice. Conversely, treatment with a neutralizing antibody to
HMGB1 provided signiﬁcant protection from I/R damage in
WT mice but aﬀorded no further protection from damage in
TLR4-deﬁcient mice. While this study showed that HMGB1
is capable of activating TLR4 in the setting of warm hepatic
I/R, we subsequently found that TLR4 activation actively
regulated the release of HMGB1 from hepatocytes. These
studies showed that circulating levels of HMGB1 were
signiﬁcantly lower in TLR-defective mice after I/R, and
we found this phenomenon to be dependent on TLR4-
dependent production of ROS and Calcium/Calmodulin-
Dependent Protein Kinase (CaMK) signaling [35]. Thus,
while HMGB1 is an activator of TLR4, its release is also
determined, in part, by TLR4 itself.
TLR4 is expressed in numerous cell types in the liver,
including parenchymal hepatocytes and bone marrow-
derived immune cells. In a study to delineate the role
of TLR4 in diﬀerent cell types of the liver, we generated
TLR4 chimeric mice and found that hepatic injury after
I/R is largely dependent on TLR4 expression on bone-
marrowderivedcells[36].Achimericmousemodelinwhich
recipient mice received lethal irradiation to eradicate bone
marrow cells, followed by bone marrow transplantation,
was used. This procedure permits reconstitution of bone
marrow with syngeneic bone marrow from mice with
either functioning or mutant TLR4 signaling. After 8–10
weeks, the immune cells within the liver are replaced with
cells expressing the new phenotype while the long-lived
parenchymal cells retain the host’s phenotype. WT mice that
lacked TLR4 on bone marrow-derived cells were protected
from I/R injury similar to mice that lacked TLR4 in both
parenchymal and bone marrow-derived cells. In contrast,
transfer of WT TLR4 bone marrow cells to Mutant TLR4
mice resulted in signiﬁcantly increased hepatocellular injury
after I/R. In addition, WT mice, but not Mutant TLR4
mice, were protected from I/R injury following phagocytic
celldepletionwithgadoliniumchloridewhileoverexpression
of dendritic cells with plasmid GM-CSF worsened damage
in WT, but not Mutant, TLR4 mice [37]. Taken together,
these data indicate that TLR4 signaling in NPCs, such as
Kupﬀer and dendritic cells, is required for I/R-induced
injury and inﬂammation. Similar results were reported in
another study by Hui et al., who reported that TLR4
expression on both bone marrow and parenchymal cells was
necessary for maximal damage after I/R. Chimeric mice that
lacked TLR4 on either bone marrow-derived or parenchymal
cells were protected from injury compared to mice with
functional signaling in both cell populations. This study also
showedthatfunctionalTLR4signalingonnonbonemarrow-
derived cells (sinusoidal endothelial cells and hepatocytes)
was necessary for the expression of ICAM-1, which adheres
to circulating neutrophils recruited to the liver following
damage. Neutrophil inﬁltration itself, however, was found to
be dependent on bone marrow-derived cells [38].
Downstream TLR4 signaling pathways include both the
MyD88 and TRIF signaling cascades, and TLR4-mediated
hepatocellular damage appears to be independent of MyD88
signaling. This insight came from a study by Zhai et al.
who used MyD88 KO and IRF3 KO mice. MyD88 KO
mice were used to study one branch of the TLR4 signaling
cascade while IRF3 KO mice were used to study TRIF-
dependentsignaling,sinceIRF3isdownstreamofTRIF.They
found that protection was not conferred to MyD88 KO mice
during I/R while IRF3 KO mice were signiﬁcantly protected
[39]. These results suggested that TRIF-dependent signaling
was critical in mediating warm I/R damage. Since TRIF-
dependent signaling activates the interferon response, these
authors undertook additional studies to delineate down-
streammediatorsandfoundthatbothType1Interferonsand
CXCL10 were critical for I/R damage in a TRIF-dependent
fashion [40, 41]. This work suggests TLR4 mediated damage
is MyD88 independent and involves activation of IRF3, type
I interferons, and production of CXCL10.Gastroenterology Research and Practice 5
Another member of the interferon regulatory factor
family, IRF1, has also been shown to be downstream of
TLR4 activation [42], and this molecule is important for
I/R injury. IRF1 KO mice are protected from hepatocellular
damage in warm I/R while in vivo adenoviral overexpression
of IRF1 augments damage [43]. Furthermore, two studies
using orthotopic liver transplantation have shown that IRF1
expression in hepatocytes is critical for mediating I/R injury
[44, 45]. Unpublished work from our group shows that
IRF1 expression during I/R is TLR4 dependent, as TLR4-
defective mice have decreased levels of IRF1 expression
after I/R. In vitro, IRF1 expression was decreased in TLR4-
deﬁcient hepatocytes, and adenoviral transfection of WT
TLR4 into these cells restored IRF1 expression. We also
found that IRF1 expression is critical for the release of the
danger signal HMGB1. We observed that serum levels of
HMGB1 in IRF1 KO mice were signiﬁcantly lower than their
wild-type counterparts, and IRF1 KO hepatocytes release
signiﬁcantly less HMGB1 into cell culture supernatants after
nonlethal hypoxic stimuli. These novel ﬁndings connect
three important mediators of I/R injury, TLR4, IRF1, and
HMGB1.
5.2. Cold I/R. TLR4 has also been implicated in cold I/R
injury during liver transplantation. Tsoulfas and colleagues
showed that components of the LPS signaling pathway were
inovolved in hepatic transplant preservation injury [46].
Subsequently, Shen et al. used an orthotopic liver transplant
(OLT) model and found that absence of TLR4 signaling
in donor livers protected recipients from hepatocellular
damage. A similar pattern of protective changes observed in
TLR4 KO grafts was observed in this model compared to
similar studies in warmI/R. These changesinclude decreased
serum ALT, CXCL10, ICAM-1, TNF-α,I L - 1 β,I L - 2 ,a n d
IFNγ and an increase in protective HO-1. These eﬀects were
observed regardless of the TLR4 genotype of the recipient
[47]. In addition to murine studies, increased expression of
TLR4 on monocytes of liver transplant patients has also been
found correlate with acute rejection [48].
6.TLR2 inLiverI/R
Although the role of TLR2 in I/R is less well delineated, a
number of studies have made important strides in determin-
ing its role. Classic TLR2 ligands include PAMPs from gram
positive bacteria including peptidoglycan and lipoteichoic
acid. Zhai and colleagues examined TLR2 KO mice in a
model of warm I/R and found no signiﬁcant diﬀerence in
serumAL T sinTLR2K OmicecomparedtoWTcontrols[30].
SimilarﬁndingswerenotedbyShenandcolleagues,whoalso
showed that TLR2 KO mice were not aﬀorded protection
in warm hepatic I/R [31]. While no studies in hepatic I/R
have identiﬁed a signiﬁcant role for TLR2 in promoting or
preventing damage, it has been implicated in other models
of I/R, namely cardiac [49, 50], renal [51, 52], brain [53–
55], and gut [56]. Taken together, these studies support the
possibility that tissue and cell-type speciﬁc roles for TLRs
exist.
7.TLR9 inLiverI/R
TLR9 is an intracellular molecule that functions as sensor
for DNA. It was originally described by Hemmi et al.
who showed that TLR9 KO mice failed to respond to
bacterial CpG DNA [57]. Upon internalization of DNA
from the plasma membrane, TLR9 translocates from the ER
to endosomes and binds DNA. Although it was originally
thought that TLR9 was speciﬁc for the recognition of
bacterialDNA,itwassubsequentlydiscoveredthathostDNA
is also capable of activating TLR9 [58–61]. In regard to
liver I/R injury, Bamboat et al. found that TLR9 KO mice
were protected from injury in warm I/R by a mechanism
dependent on TLR9 expression on liver nonparenchymal
cells. Using chimeric mice generated from adoptive bone
marrow transfer, they reported that TLR9 expression on
bone marrow-derived cells, but not liver parenchymal cells,
to be important for damage after I/R [62]. In vitro experi-
ments with hepatocytes and NPCs derived from TLR9 WT
andKOmicesuggestedthatDNAderived fromnecrotichep-
atocytes was capable of activating TLR9-competent NPCs,
causing increased production of proinﬂammatory cytokines.
In contrast to its overall eﬀect in liver I/R, a recent report
from the same group showed that secretion of the anti-
inﬂammatory cytokine IL-10 from conventional dendritic
cells (cDCs) during liver I/R is TLR9 dependent. Depletion
of cDCs resulted in increased liver damage after I/R, and
this phenomenon could be reversed by exogenous transfer of
WT cDCs prior to I/R. However, transfer of TLR9−/− cDCs
failed to rescue mice from increased damage, suggesting that
T L R 9a c t i v a t i o ni nc D C si sp r o t e c t i v e[ 63]. These ﬁndings
are in contrast to a report by our group, which demonstrated
that DCs promote I/R injury through a TLR4-dependent
pathway involving HMGB1 [37]. The seemingly conﬂicting
roles of liver DC in liver I/R may be due to diﬀerences in
the deﬁnition of DCs used in these studies. DC markers
such as CD11c may be expressed in a wide variety of both
intrahepatic leukocytes and nonhematopoietic cells [64, 65].
Thus, the role of various TLRs on DCs in modulating
the hepatic microenvironment following I/R remains to be
fully elucidated. These future studies will require stricter
validation to determine that the cells being analyzed are
indeed morphologically DCs.
8. Conclusion
Taken together, the results of the studies summarized in this
paper provide convincing evidence demonstrating that TLR
signaling is involved in the early activation of the innate
immune system in the setting of I/R injury. Accumulating
evidence points to endogenous molecules that are released
from stressed or damaged cells or tissues during the course
of I/R, as important triggers of the immune response in
the setting of I/R (Figure 2). While much of the early
work focused on the role of TLR4, new and future work
will continue to delineate the roles of other TLRs in I/R
injury. A better understanding of the molecular interactions
involved in these processes, as well as greater knowledge
of the intracellular pathways that mediate these signaling6 Gastroenterology Research and Practice
cascades, may ultimately allow for the development of
therapeutics aimed at ameliorating I/R injury and its adverse
consequences.
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